Skip to Content

The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients

In this MEDtalk, Camille Hamm discusses a study that focused on interclass switching within the IL-23 class of biologics for the treatment of psoriasis. The study specifically looked at patients who had failed to respond to the drug guselkumab and were subsequently switched to risankizumab to evaluate the effectiveness of this switch.

Camille Hamm

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top